Marilizabeth Birk
Psychiatric/Mental Health · Phoenix, AZNPI 1306453220
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 66.8% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $28,060, more than ten times the $434 reported in 2022. Among psychiatric/mental health clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 403 payments — averaging $83.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$23K
- E.r. Squibb & Sons, L.L.C.$3K
- Teva Pharmaceuticals USA, Inc.$2K
- Alkermes, Inc.$1K
- Johnson & Johnson$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- plus $3K from 11 others
What the payments were for
- Consulting fees$2,4107%
- Speaking & faculty fees$15,10045%
- Travel & lodging$4,86714%
- Food & beverage$11,14033%
- Education$1620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 147 | $22,503 |
| E.r. Squibb & Sons, L.L.C. | 26 | $2,707 |
| Teva Pharmaceuticals USA, Inc. | 45 | $1,713 |
| Alkermes, Inc. | 32 | $1,481 |
| Johnson & Johnson | 32 | $1,362 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 52 | $1,262 |
| Otsuka America Pharmaceutical, Inc. | 27 | $840 |
| Neurocrine Biosciences, Inc. | 9 | $514 |
| Janssen Scientific Affairs, LLC | 4 | $348 |
| Axsome Therapeutics, Inc. | 4 | $298 |
| Vanda Pharmaceuticals Inc. | 10 | $233 |
| Supernus Pharmaceuticals, Inc. | 5 | $199 |
| Corium, LLC | 5 | $90 |
| Bristol Myers Squibb | 1 | $55 |
| Tris Pharma Inc | 2 | $39 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Luye Pharma (USA) Ltd. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$15,895
- LYBALVI$893
- INVEGA SUSTENNA$809
- VIVITROL$673
- CAPLYTA$610
- UZEDY$457
- COBENFY$388
- INGREZZA$376
- INVEGA TRINZA$256
- Auvelity$247
- ABILIFY MAINTENA$242
- ABILIFY ASIMTUFII$242
- Austedo XR$234
- QELBREE$125
- REXULTI$122
- SPRAVATO$117
How this compares
$33,679 in reported general payments places this provider in the 95th percentile of 1,230 psychiatric/mental health providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 41 | $336,470 |
| VraylarCariprazine Hcl | 28 | $44,250 |
| CaplytaLumateperone Tosylate | 25 | $43,518 |
| Invega SustennaPaliperidone Palmitate | 12 | $31,556 |
| Divalproex Sodium | 18 | $3,385 |
| Adderall XrDextroamphetamine/Amphetamine | 13 | $3,118 |
| Divalproex Sodium ErDivalproex Sodium | 30 | $2,585 |
| Quetiapine Fumarate | 86 | $2,025 |
| Buspirone Hcl | 87 | $1,728 |
| Aripiprazole | 56 | $1,682 |
| Duloxetine Hcl | 67 | $1,595 |
| Trazodone Hcl | 119 | $1,464 |
| Atomoxetine Hcl | 18 | $1,453 |
| Naltrexone Hcl | 32 | $1,402 |
| Olanzapine | 36 | $1,249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $514 | $336,47041 claims |
| AbbVieVraylar | $22,503 | $44,25028 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,262 | $43,51825 claims |
| Johnson & JohnsonInvega Sustenna | $1,362 | $31,55612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,230 psychiatric/mental health providers in Arizona.
Other psychiatric/mental health in Phoenix
- Elizabeth ElliottPhoenix$363K
- Russell HorningPhoenix$254K
- Claire ReecePhoenix$88K
- Luis FongPhoenix$59K
- Jaime LecomtePhoenix$15K
- Roger MayorgaPhoenix$10K
- Elena SassPhoenix$9K
- Martha SerranoPhoenix$8K
- Bonnie VogesPhoenix$7K
- Brandy HammondPhoenix$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.